Profile data is unavailable for this security.
About the company
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
- Revenue in CAD (TTM)413.17k
- Net income in CAD-2.68m
- Incorporated2013
- Employees12.00
- LocationAequus Pharmaceuticals IncSuite 2820, 200 Granville StreetVANCOUVER V6C 1S4CanadaCAN
- Phone+1 (604) 336-7906
- Fax+1 (604) 336-7906
- Websitehttps://www.aequuspharma.ca/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aequus Pharmaceuticals Inc | 413.17k | -2.68m | 663.17k | 12.00 | -- | -- | -- | 1.61 | -0.0202 | -0.0202 | 0.0031 | -0.0469 | 0.4071 | 1.36 | 6.12 | -- | -263.64 | -97.96 | -- | -293.31 | 53.45 | -- | -647.61 | -141.53 | 0.0315 | -10.66 | 20.49 | -- | -81.53 | -28.97 | 7.64 | -- | -- | -- |
| Vitality Products Inc | 766.56k | -153.51k | 828.23k | -- | -- | -- | -- | 1.08 | -0.0037 | -0.0037 | 0.0185 | -0.0345 | 0.9206 | 1.12 | 7.02 | -- | -18.44 | -28.04 | -- | -- | 72.79 | 73.72 | -20.03 | -42.49 | 0.1453 | -- | -- | -- | -4.76 | 8.31 | 49.92 | -- | -0.619 | -- |
| Hill Inc | 2.21m | -1.62m | 837.11k | -- | -- | 12.11 | -- | 0.3792 | -0.4977 | -0.4977 | 0.677 | 0.0211 | 0.5822 | 11.26 | 4.55 | -- | -42.86 | -56.07 | -48.68 | -70.16 | 60.74 | 53.77 | -73.61 | -106.94 | 1.28 | -5.83 | 0.9749 | -- | -23.45 | 11.51 | 22.89 | -- | -- | -- |
| Lumiera Health Inc | 606.45k | -2.41m | 864.84k | -- | -- | -- | -- | 1.43 | -0.0142 | -0.0142 | 0.0036 | -0.014 | 0.5096 | 2.13 | 11.78 | -- | -202.92 | -- | -- | -- | 13.17 | -- | -398.18 | -- | 0.0395 | -2.10 | -- | -- | 46.91 | -- | -188.58 | -- | -- | -- |
